OXOLIFE

OXOLIFE is a small-size clinical-stage company founded in 2013, headquartered in Spain, with a focus on female fertility. The company's slogan, "Enhancing embryo implantation. Improving women’s fertility," encapsulates its core mission. OXOLIFE is currently developing an innovative treatment, OXO-001, aimed at enhancing female fertility success and improving embryo implantation through a direct effect on the endometrium. Additionally, the company is conducting research to address PCOS-related infertility. Notably, OXO-001 is a first-in-class drug with a unique mechanism of action, addressing an unmet medical need in the embryo implantation segment. The latest investment of €2.40M Grant was secured on 13 December 2022 from the Ministry of Science and Innovation of Spain. This funding is crucial as it supports the advancement of OXOLIFE's development and clinical trials. The company's leadership, including Agnès Arbat, Medical Doctor (Co-founder and CEO), and Ignasi Canals, Biochemist PhD (Co-founder and CSO), brings extensive experience in the Women’s health pharmaceutical industry and drug development. OXOLIFE also benefits from continuous support from Clinical and Scientific Opinion Leaders from prestigious fertility and R&D centers. As OXOLIFE progresses through its phase II clinical trial with promising primary results, anticipated to be completed by the end of 2023, the company is poised to enter the final stages of clinical development. With its innovative approach and dedicated team, OXOLIFE is well-positioned to address critical challenges in women's health and fertility, offering potential opportunities for impactful advancements in the biotechnology and healthcare industries.